GPCR Structure Therapeutics
- 33.740
- -0.270-0.79%
- 33.720
- -0.020-0.06%
Structure Therapeutics News
Morgan Stanley Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $118
Jefferies Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $79
BMO Capital Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $100
Piper Sandler Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $93
Piper Sandler Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $93
Piper Sandler Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
BMO Capital Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $100
Cantor Fitzgerald Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $65
Structure Therapeutics Price Target Announced at $118.00/Share by Morgan Stanley
Cantor Fitzgerald Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Morgan Stanley Initiates Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $118
Structure Therapeutics Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target
JMP Securities Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $86
Buy Rating on Structure Therapeutics: Promising GSBR-1290 Clinical Developments and Competitive Market Positioning
Jefferies Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $79
Piper Sandler Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $93
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy From Piper Sandler
Structure Therapeutics Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target
Analysis
Price Target
No Data
No Data
